Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Wolf-Hirschhorn syndrome candidate 1 pseudogene" designates a genomic sequence with strong similarity to the functional WHSC1 (NSD2) gene but lacks coding capacity and does not result in an active protein. It is not considered a therapeutic or biological target. The canonical WHSC1 gene encodes a histone methyltransferase involved in epigenetic regulation, cell differentiation, and has documented roles in cancer and Wolf-Hirschhorn syndrome, but these properties do not apply to the pseudogene form[3][4]. Queries for "WHSC1" typically refer to the protein-coding gene, not the pseudogene, and the pseudogene lacks clinical or therapeutic significance. Important distinction: If you require information for the functional gene or protein (WHSC1/NSD2, a histone methyltransferase with clinical relevance), please specify; this answer addresses only the pseudogene, which is not a functional or therapeutic target and should not be used in the context of pharmacology or molecular function[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wolf-Hirschhorn syndrome candidate 1 pseudogene.